RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Clinical trials for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at two hard-to-treat blood cancers
Disease control Recruiting nowThis early-phase trial tests a new treatment using specially engineered immune cells (CAR-NK cells) that target a protein called CD70 found on cancer cells. The study enrolls 25 adults with T-cell lymphoma or acute myeloid leukemia that has come back or not responded to standard …
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 17, 2026 05:21 UTC
-
New hope for tough leukemia: experimental drug targets resistant cancers
Disease control Recruiting nowThis early-stage study tests an experimental drug called NMS-03597812 in about 124 adults whose acute myeloid leukemia has returned or not responded to standard treatments, including those with a TP53 gene mutation. The main goals are to check the drug's safety, find the right do…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: Nerviano Medical Sciences • Aim: Disease control
Last updated May 17, 2026 05:21 UTC
-
New hope for tough leukemia: experimental drug BL-M11D1 enters human testing
Disease control Recruiting nowThis early-phase study tests an experimental drug called BL-M11D1 in about 120 adults whose acute myeloid leukemia has returned or not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it helps control the cancer. Par…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated May 17, 2026 05:05 UTC
-
New hope for tough leukemia: drug combo trial launches
Disease control Recruiting nowThis study compares two drug combinations for people whose acute myeloid leukemia (AML) has returned or not responded to treatment. About 200 participants aged 14 to 75 will receive either venetoclax plus CACAG or the standard BAT regimen. The goal is to see which combo leads to …
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated May 15, 2026 11:53 UTC